{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-224022","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2026-05-14T20:10:17+00:00","discovered_at":"2026-05-14T20:11:00.325340+00:00","generated_at":"2026-05-14T20:12:45.847356+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AVITA Medical Q1 revenue $19.3M (+4% YoY); net loss narrows to $10.6M","bullets":["Total revenue $19.3M, up 4% YoY and 10% sequentially, driven by Cohealyx and improved RECELL utilization.","Net loss $10.6M ($0.35 loss per share) vs $13.9M ($0.53 loss) in Q1 2025; operating expenses down 11% to $24.5M.","Gross profit margin 81.7% (vs 84.7%) due to product mix; RECELL-only margin 85.0%.","Reaffirmed FY2026 revenue guidance $80-85M, representing growth of 12-19%.","Appointed Cary Vance as President and CEO; Jan Stern Reed as independent Chair of the Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-224022","json":"https://secwatch.observer/filing/0001193125-26-224022.json","markdown":"https://secwatch.observer/filing/0001193125-26-224022.md","text":"https://secwatch.observer/filing/0001193125-26-224022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000119312526224022/0001193125-26-224022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000119312526224022/rcel-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:12:45.847356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92e23daaccfc1e99ebd1bca92e6761c48c0227c6","claim":"AVITA Medical, Inc. reported first quarter ended March 31, 2026 results: revenue approximately $19.3 million, net income $10.6 million, EPS $0.35 per basic and diluted share. Guidance reaffirmed.","evidence_excerpt":"today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights and Recent Business Updates • Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by contributions from Cohealyx ® and improved RECELL ® utilization as reimbursement dynamics normalize •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000119312526224022/0001193125-26-224022-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"approximately $19.3 million"},{"label":"Net income","value":"$10.6 million"},{"label":"EPS","value":"$0.35 per basic and diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}